White House Peptide Review: What OIRA’s Decision Means

The OIRA conclusion record identifies “Interim Access Policy for Compounding Using Certain Peptides,” RIN 0910-ZD94. It lists HHS/FDA as the agency and subagency, “Notice” as the stage, October 14, 2026 as the received date, and October 27 as the conclusion date. The concluded action is “Consistent with Change.”

These fields are more precise than “the White House approved peptides.” They identify a particular policy submission and its review outcome. The record does not list approved drug applications, approved indications, patient populations, or prescription labeling. Readers should not add those meanings to an administrative review entry.

OIRA is the Office of Information and Regulatory Affairs within the Office of Management and Budget. The public record is hosted on Reginfo.gov, the official OMB and General Services Administration site. Referring to this as White House regulatory review describes its institutional location. It does not mean the President personally evaluated a drug application.

A useful way to read the record is to ask what object was reviewed. Here, it was an interim access policy at the notice stage. The object was not an individual vial, a pharmacy’s preparation, or a clinical claim about injury recovery. The conclusion belongs to the policy review and should stay attached to it.

It tells us the review concluded under that recorded outcome. The short public entry does not, by itself, provide a line-by-line account of changes or who requested each one. Without supporting documents, it would be speculation to attribute a particular patient-disclosure sentence or chemical-form restriction to White House staff.

The next document readers need is the HHS policy itself. That is where the covered substances and conditions are explained. Comparing the review record with the issued text also prevents a common mistake: treating an earlier proposal title as the full operative description of the later document. Process metadata and policy content answer different questions.

The Federal Register public-inspection notice announces the policy’s availability and is signed by HHS Secretary Robert F. Kennedy Jr. It calls the policy draft, describes interim enforcement discretion, and schedules Federal Register publication for October 30. These qualifiers remain important even after the OIRA review has concluded.

The notice expressly says compounded drugs are not FDA-approved. It describes future rulemaking that may propose adding some or all of the substances to the 503A bulks list. That future possibility is not completed by an OIRA conclusion on this notice. A review milestone does not silently replace the additional processes mentioned in the agency’s own text.

Check the specific concluded-review record rather than relying only on an older search snippet saying “Pending Review.” During a fast-moving announcement, a news article or indexed dashboard may still reflect the earlier state. Match the RIN and title so you are comparing the same policy rather than another FDA action.

Then read the latest HHS policy and the published Federal Register notice when available. Keep dates distinct: receipt, review conclusion, public inspection, publication, and any separately specified effective date are not interchangeable. Our timeline organizes those events. For patients, none of these administrative dates substitutes for an individualized discussion about evidence, alternatives, risks, and the exact product under consideration.